INSP · Inspire Medical Systems, Inc.

Current Thesis

Inspire Medical Systems' rally prices a recovery from reimbursement disruption; a weekly close at or above Stifel's September 11 target of $80 would confirm the price case, while a weekly close below the September 11 reference close of $73 would invalidate it. This is an inference about expectations: the August 3 earnings release still reported declining revenue. Stifel target report, September 11, company earnings release, August 3.

The narrative is accelerating — the supplied September 11 price series shows a three-month gain of 71.0%, and Stifel analyst Jonathan Block raised his target to $80 from $75 that day. That classification describes renewed attention, not demonstrated revenue recovery; failure of the $73 weekly-close condition would overturn this continuation case. September 11 analyst report.

Bullish and bearish views on Inspire Medical Systems, Inc.

The model's bull view on Inspire Medical Systems, Inc. (INSP), in brief: Product mix supports margins. For the quarter ended June 30, 2026, gross margin reached 85.5%, an increase of 150 basis points; Inspire attributed the improvement primarily to greater Inspire V system sales mix. August 3 earnings release. Coding application addresses disruption.… The bear view: Revenue recovery remains unproven. Second-quarter 2026 revenue fell 7.6% year over year to $200.6 million. Inspire attributed the U.S. decline primarily to the changing coding and reimbursement environment. August 3 earnings release. Cash improvement has limits. Second-quarter… Both cases follow in full.

Bull Case

• Product mix supports margins. For the quarter ended June 30, 2026, gross margin reached 85.5%, an increase of 150 basis points; Inspire attributed the improvement primarily to greater Inspire V system sales mix. August 3 earnings release.
• Coding application addresses disruption. Inspire's June 26 presentation disclosed a new application submitted June 10 for a single-lead procedure code, with additional clinical evidence and participation from multiple industry participants. Management expected September review; rejection would defeat this proposed route to a durable coding solution. June 26 company presentation.

Bear Case

• Revenue recovery remains unproven. Second-quarter 2026 revenue fell 7.6% year over year to $200.6 million. Inspire attributed the U.S. decline primarily to the changing coding and reimbursement environment. August 3 earnings release.
• Cash improvement has limits. Second-quarter 2026 operating cash flow was $23.2 million, with improvement primarily attributed to working capital. The same quarter recorded an operating loss of $0.5 million. August 3 earnings release.
• Approval would precede implementation. The June 26 presentation identified January 1, 2028 as the proposed code's effective date if approved. September review therefore cannot itself establish immediate implementation. Company coding presentation.

Setup & Price Structure

The supplied adjusted market series records a September 11, 2026 close of $73.00, a three-month price increase of 71.0%, and a 14-period relative strength index (RSI) of 74.3. Despite that rebound, the shares remained 49.3% below the series' 52-week high of $143.99. These observations establish strong recent momentum within a much larger decline.

The $73 reference close is the explicit research threshold, not an independently verified support shelf. No moving-average values, trading-volume series or repeated tests of support were supplied. The narrow continuation case reaches its observable price outcome at a weekly close at or above Stifel's September 11 target of $80, before a weekly close below $73 occurs. Stifel target attribution.

Benzinga's September 10, 2026 healthcare momentum article included Inspire among stocks with RSI readings above 70, according to the supplied news summary. That establishes retail-facing coverage of the rebound. The sample is too small to support a claim about coverage clustering or crowded ownership; no short-interest, fund-flow or insider-transaction evidence establishes positioning here.

Catalyst Calendar (next 30 days)

• 2026-09-16 — Therapy presentation. Inspire's corporate announcement schedules an Inspire therapy product theater at the ASCENT annual conference. This is a dated commercial-education event; the announcement does not promise financial results or a reimbursement decision. Company announcement.
• 2026-09-13–2026-10-13 — Coding-review monitoring window. Inspire's June 26 presentation expected review at the September 2026 American Medical Association Current Procedural Terminology (CPT) meeting. The exact panel date and public decision date were not verified; this interval is the dossier's calendar window, not a confirmed event schedule. Company presentation.
• ~2026-11-02 (est.) — Third-quarter earnings. MarketBeat's September 11 calendar estimates this reporting date; it is outside the next month and remains unconfirmed by the company. The report would test whether the revenue contraction described on August 3 has eased. Estimated earnings calendar.

What Would Change Our Mind

Loss of the September 11 reference close would break the published continuation thesis: a weekly close below $73 is the price invalidation. That condition deliberately tests whether the latest measured advance persists; it does not claim that a historical base exists at that level.

Rejection of the coding application described in Inspire's June 26 presentation would separately undermine the reimbursement-recovery explanation. A September meeting without a public announcement would leave the outcome unresolved, rather than prove rejection. Approval would support the coding argument, but the company's proposed January 1, 2028 effective date means that near-term revenue recovery still requires separate financial evidence. Company coding presentation.

Correlation Notes

FrontierPicks' supplied Medtech & diagnostics classification moved from accelerating on August 30, 2026 to maturing on September 6 and saturated on September 13. Those are editorial assessments of the group, not measured fund flows or a verdict on Inspire. The single-name acceleration inference rests instead on the September 11 price observations and Stifel revision.

The supplied peer group comprises HTFL, ATRC, PRPO, BFLY and TXG, but no matched return series was provided as of September 13, 2026. The evidence does not support a numerical correlation estimate or a claim that group participation confirms Inspire's advance.